Verificando…
Traducido automáticamente. Dosis y advertencias: consulta el original en inglés. Leer en inglés
Inicio / Registrado en Nigeria / Nepafenac Ophthalmic Suspension

Nepafenac Ophthalmic Suspension

NAFDAC Reg. No. B4-5603 Estupefaciente

Registrado en NAFDAC. Registro activoAs of 18 November 2026 · synced automatically from official sources.
Producto
Nepafenac Ophthalmic Suspension
Número NAFDAC
B4-5603
Principio activo
Nepafenac
Dosis
0.1%
Forma
Suspension/Drops
Tamaño del envase
1 x 5 mL (in plastic bottle)
Fabricante
No Constan
Solicitante (titular)
Lin-Kabs Pharmaceutical Limited
Approved
28 Sep 2021
Estado
Inactive Ver en NAFDAC ↗
Registro válido hasta
27 Sep 2026
Alertas de la OMS
No se ha encontrado ninguno
Informes de la comunidad
Ninguno
Tiempos comprobados
0

Pero sobre el medicamento, Nepafenac: uses, dosage and brands worldwide

Lo que encontramos

  • Nepafenac Ophthalmic Suspension is on the NAFDAC register with an active registration (B4-5603). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generado automáticamente a partir del registro NAFDAC, QUIÉN alerta y los datos de la comunidad a partir de hoy. Este no es un consejo médico. Siga siempre a su médico o farmacéutico.

How to use Nepafenac Ophthalmic Suspension

Lo que dice el prospecto oficial. Si te lo recetó un médico, sigue la receta. Si el prospecto de tu caja es distinto, manda el de tu caja.

Para quién es

ILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ILEVRO ® 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 ).

Cómo tomarlo y con qué frecuencia
  • One drop of ILEVRO ® 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period
  • An additional drop should be administered 30 to 120 minutes prior to surgery
  • Recommended Dosing One drop of ILEVRO ® 0.3% should be applied to the affected eye one time daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period
  • An additional drop should be administered 30 to 120 minutes prior to surgery
  • Use with Other Topical Ophthalmic Medications ILEVRO ® 0.3% may be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics
  • If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart
Fortalezas en las que viene

Sterile ophthalmic suspension 0.3%: 1.7 mL in a 4 mL bottle and 3 mL in a 4 mL bottle. Sterile ophthalmic suspension 0.3%: 3 mL in a 4 mL bottle. ( 3 )

Infancia

The safety and effectiveness of ILEVRO ® 0.3% in pediatric patients below the age of 10 years have not been established.

Older adults

No overall differences in safety and effectiveness have been observed between elderly and younger patients.

While you are taking it
  • Slow or Delayed Healing Inform the patient of the possibility that slow or delayed healing may occur while using NSAIDs [see Warnings and Precautions ]
  • Avoiding Contamination of the Product Instruct the patient to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections
  • Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions
  • Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery. …
Talk to a doctor first if
  • ILEVRO ® 0.3% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDS)
Warnings

Increased bleeding time due to interference with thrombocyte aggregation ( 5.1 ) Delayed healing ( 5.2 ) Corneal effects including keratitis ( 5.3 ) 5.1 Increased Bleeding Time With some NSAIDs including ILEVRO ® 0.3%, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery. It is recommended that ILEVRO ® 0.3% be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. …

Posibles efectos secundarios

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice. Most common adverse reactions (5% to 10%) are capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Harrow Eye, LLC at 1-833-4HARROW or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . …

Pregnancy and breastfeeding

8.1 Pregnancy Teratogenic Effects. Pregnancy Category C: Reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. …

Si olvidas una dosis

Tómala en cuanto te acuerdes, salvo que falte poco para la siguiente. En ese caso, sáltate la olvidada. Nunca tomes dos dosis a la vez para compensar. Revisa tu prospecto, porque algunos medicamentos son distintos.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-04-01.

Label for nepafenac, the active ingredient registered with NAFDAC.

Check your pack of Nepafenac Ophthalmic Suspension

Add the expiry date on your pack for a full Trust Score.

O haz fotos de la caja
Te quedan 3 verificaciones gratis hoy Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Nepafenac Ophthalmic Suspension

What is in Nepafenac Ophthalmic Suspension?

Nepafenac Ophthalmic Suspension contains Nepafenac (0.1%), as suspension/drops, according to its NAFDAC registration record.

Is Nepafenac Ophthalmic Suspension registered with NAFDAC?

Yes. Nepafenac Ophthalmic Suspension is listed on the NAFDAC register under registration number B4-5603, and its registration is active as of 18 November 2026.

Has Nepafenac Ophthalmic Suspension been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Nepafenac Ophthalmic Suspension in our automatically synced alert list.

How can I check that my pack of Nepafenac Ophthalmic Suspension is genuine?

Run a free authenticity scan with the NAFDAC number B4-5603, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Nepafenac Ophthalmic Suspension?

Follow your prescription or the leaflet in your pack. The official label says: One drop of ILEVRO ® 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery. ( 2 ) 2.1 Recommended Dosing One drop of ILEVRO ® 0.3% should be applied to the affected …

What is Nepafenac Ophthalmic Suspension used for?

ILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ILEVRO ® 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 ). (Summarised from the official U.S. FDA label for nepafenac. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Nepafenac Ophthalmic Suspension? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.